Bio News

Genentech has entered a partnership with China’s DualityBio to develop an antibody-drug conjugate (ADC) cancer treatment. Genentech will pay $45 million upfront and up to $1 billion (approximately 1.38 trillion won) in milestone payments. DualityBio will handle drug discovery and early development, while Genentech will take over development after the phase 1a clinical trial.

BIOBOOK TEAM
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia